2 results
Approved WMOCompleted
The objective of this open label phase IIa trial is to evaluate the efficacy and tolerability of a once a week dose of 200 mg R126638, for a maximum of 12 weeks, for the treatment of toenail onychomycosis.
Approved WMOWill not start
Collect clinical data in order to confirm the clinical safety and performance of the Pamira lead when used in routine clinical practice to support the regulatory post-market strategy in Europe and other regions and validation of promotional claims…